Physician profile
Sharad Kothari
NPI 1245462621
$2,464.09
in general payments reported to CMS, 2019-2025
25 companies · $581 in 2025
The $581 reported for 2025 was more than what 81% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2021: $195 · 2022: $511 · 2023: $430 · 2024: $368 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $379.40 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $372.56 | 2019-2022 | |
| Amgen INC. | $272.51 | 2019-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $266.21 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $160.41 | 2021-2025 | Breztri, Airsupra |
| Abbvie INC. | $143.97 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $128.87 | 2021-2023 | Austedo Xr, Austedo |
| Viatris Specialty LLC | $125.00 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $116.15 | 2021-2024 | |
| Lilly USA, LLC | $82.45 | 2019-2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.77 | 2019-2025 | Xifaxan |
| Pfizer INC. | $54.30 | 2019-2023 | |
| Shield Therapeutics INC | $42.91 | 2025 | |
| Azurity Pharmaceuticals, INC. | $34.81 | 2024 | Horizant |
| Acorda Therapeutics, INC | $28.91 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $27.24 | 2025 | |
| Merck Sharp & Dohme LLC | $26.24 | 2019 | |
| Corium, LLC | $24.23 | 2023 | Adlarity |
| Takeda Pharmaceuticals U.S.A., INC. | $22.45 | 2019 | |
| Shire North American Group INC | $22.03 | 2019 | |
| Radius Health, INC. | $18.91 | 2019 | |
| Exact Sciences Corporation | $16.64 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $15.00 | 2019 | |
| Amarin Pharma, INC. | $14.20 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharad Kothari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.